Marketing Models for the Life Sciences Industry
暂无分享,去创建一个
[1] R. Kravitz,et al. Request Fulfillment in Office Practice: Antecedents and Relationship to Outcomes , 2002, Medical care.
[2] Ceren Kolsarici,et al. Category- versus Brand-Level Advertising Messages in a Highly Regulated Environment , 2010 .
[3] T. Valente. Social network thresholds in the diffusion of innovations , 1996 .
[4] G. Lilien,et al. Medical Innovation Revisited: Social Contagion versus Marketing Effort1 , 2001, American Journal of Sociology.
[5] Sachin Gupta,et al. An Empirical Model of Drug Detailing: Dynamic Competition and Policy Implications , 2015 .
[6] W. S. Comanor,et al. Strategic Pricing of New Pharmaceuticals , 1998, Review of Economics and Statistics.
[7] Lakshman Krishnamurthi,et al. The Advantages of Entry in the Growth Stage of the Product Life Cycle: An Empirical Analysis , 1999 .
[8] Pradeep K. Chintagunta,et al. New Drug Diffusion when Forward-Looking Physicians Learn from Patient Feedback and Detailing , 2012 .
[9] M. Wosinska,et al. Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products , 2002 .
[10] Harikesh S. Nair,et al. Asymmetric Social Interactions in Physician Prescription Behavior: The Role of Opinion Leaders , 2008 .
[11] Jacob Goldenberg,et al. Riding the Saddle: How Cross-Market Communications Can Create a Major Slump in Sales , 2002 .
[12] M. Kyle,et al. Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales* , 2002, The Journal of Law and Economics.
[13] Wei Zhang,et al. Understanding Responses to Contradictory Information About Products , 2011, Mark. Sci..
[14] D. Lundin. Moral hazard in physician prescription behavior. , 2000, Journal of health economics.
[15] Anusua Datta,et al. Effects of Physician‐directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence , 2013, Health economics.
[16] Qiang Liu,et al. The Impact of Direct-to-Consumer Advertising of Prescription Drugs on Physician Visits and Drug Requests: Empirical Findings and Public Policy Implications , 2011 .
[17] Masataka Yamada,et al. Forecasting with a repeat purchase diffusion model , 1988 .
[18] Stefan Stremersch,et al. Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes , 2008, Mark. Sci..
[19] M. F. Luce,et al. Understanding High-Stakes Consumer Decisions: Mammography Adherence Following False-Alarm Test Results , 2003 .
[20] G. Jin,et al. Direct to Consumer Advertising and Prescription Choice , 2007 .
[21] Ernst R Berndt,et al. Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression , 2004, Medical care.
[22] Peter E. Rossi,et al. Response Modeling with Nonrandom Marketing-Mix Variables , 2004 .
[23] F. Bass. A new product growth model for consumer durables , 1976 .
[24] Kurt R. Brekke,et al. Direct-to-Consumer Advertising in Pharmaceutical Markets , 2005, Journal of health economics.
[25] Stefan Stremersch,et al. Health and marketing: The emergence of a new field of research ☆ , 2008 .
[26] C. Bulte. New Product Diffusion Acceleration: Measurement and Analysis , 2000 .
[27] Shantanu Dutta,et al. Physicians' Persistence and its Implications for Their Response to Promotion of Prescription Drugs , 2008, Manag. Sci..
[28] Sridhar Narayanan,et al. Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions , 2004 .
[29] Pradeep K. Chintagunta,et al. Strategic Pricing and Detailing Behavior in International Markets , 2005 .
[30] M. Ekelund,et al. Pharmaceutical Pricing in a Regulated Market , 2003, Review of Economics and Statistics.
[31] Stefan Stremersch,et al. Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field , 2009 .
[32] Jae Young Lee,et al. Social Contagion in New Product Trial and Repeat , 2015, Mark. Sci..
[33] D. Salkever,et al. "Generic Entry and the Pricing of Pharmaceuticals" , 1995 .
[34] Sridhar Narayanan,et al. Heterogeneous Learning and the Targeting of Marketing Communication for New Products , 2009, Mark. Sci..
[35] Kurt R. Brekke,et al. Price Regulation and Parallel Imports of Pharmaceuticals , 2014 .
[36] J. Hellerstein,et al. The importance of the physician in the generic versus trade-name prescription decision. , 1998, The Rand journal of economics.
[37] Pradeep K. Chintagunta,et al. Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis , 2004 .
[38] Thomas W. Valente,et al. Opinion Leadership and Social Contagion in New Product Diffusion , 2011, Mark. Sci..
[39] P. Leeflang,et al. Why Do Firms Invest in Consumer Advertising with Limited Sales Response? A Shareholder Perspective , 2011 .
[40] G. Jin,et al. The Effect of Prescription Drug Advertising on Doctor Visits , 2005 .
[41] Puneet Manchanda,et al. A new multivariate count data model to study multi-category physician prescription behavior , 2011 .
[42] Leonard J. Parsons,et al. Analysis of Sales Call Effectiveness , 1981 .
[43] Jongkuk Lee,et al. The Timing of Codevelopment Alliances in New Product Development Processes: Returns for Upstream and Downstream Partners , 2015 .
[44] Ricardo Montoya,et al. Dynamic Allocation of Pharmaceutical Detailing and Sampling for Long-Term Profitability , 2010, Mark. Sci..
[45] The effect of customer empowerment on adherence to expert advice , 2014 .
[46] Tammo H. A. Bijmolt,et al. Generalizations on the effectiveness of pharmaceutical promotional expenditures , 2008 .
[47] Sönke Albers,et al. Personal Selling Elasticities: A Meta-Analysis , 2010 .
[48] Sriram Venkataraman,et al. The Relationship between DTCA, Drug Requests and Prescriptions: Uncovering Variation in Specialty and Space , 2012, Mark. Sci..
[49] Min Ding,et al. Counting chickens before the eggs hatch: Associating new product development portfolios with shareholder expectations in the pharmaceutical sector , 2008 .
[50] S. Dutta,et al. Portfolios of Interfirm Agreements in Technology-Intensive Markets: Consequences for Innovation and Profitability , 2004 .
[51] Henry G. Grabowski,et al. Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act , 1992, The Journal of Law and Economics.
[52] Jennifer L. Burton,et al. Patient empowerment: A cross-disease exploration of antecedents and consequences , 2015 .
[53] Stephane Jacobzone,et al. Pharmaceutical Policies in OECD Countries , 2000 .
[54] Bas Donkers,et al. Predictably Non-Bayesian: Quantifying Salience Effects in Physician Learning About Drug Quality , 2011, Mark. Sci..
[55] Füsun F. Gönül,et al. Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior , 2001 .
[56] Ying Xie,et al. The Role of Targeted Communication and Contagion in Product Adoption , 2008, Mark. Sci..
[57] J. Rizzo,et al. Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs* , 1999, The Journal of Law and Economics.
[58] S. Majumdar,et al. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study , 2008, BMJ : British Medical Journal.
[59] D. Strang,et al. Spatial and Temporal Heterogeneity in Diffusion , 1993, American Journal of Sociology.
[60] M. Kyle. The Role of Firm Characteristics in Pharmaceutical Product Launches , 2006 .
[61] J. Lanjouw. Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry , 2005 .
[62] C. Sismeiro,et al. Perception Spillovers across Competing Brands: A Disaggregate Model of how and When , 2008 .
[63] M S Wilkes,et al. Direct-to-consumer prescription drug advertising: trends, impact, and implications. , 2000, Health affairs.
[64] M. Wosinska. Direct-to-Consumer Advertising and Drug Therapy Compliance , 2005 .
[65] M. Kyle,et al. Intellectual Property Rights and Access to Innovation: Evidence from Trips , 2014 .
[66] R. Discenza,et al. Increasing the odds of patient compliance through prescription warning labels. , 1987, Journal of health care marketing.
[67] Atul Nerkar,et al. Acquisition Integration and Productivity Losses in the Technical Core: Disruption of Inventors in Acquired Companies , 2006, Organ. Sci..
[68] Stefan Stremersch,et al. Social Contagion and Income Heterogeneity in New Product Diffusion: A Meta-Analytic Test , 2004 .
[69] Carrie M. Heilman,et al. Determinants of Product-Use Compliance Behavior , 2004 .
[70] A. Shiell,et al. Do fee descriptors influence treatment choices in general practice? A multilevel discrete choice model. , 1997, Journal of health economics.
[71] Andrew A. Signore,et al. Pharmaceutical Industry Profile , 2005 .
[72] Richard E. Caves,et al. Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry , 1991 .
[73] Sriram Venkataraman,et al. The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link? , 2007, Manag. Sci..
[74] P. Geoffard,et al. Therapeutic non-adherence: a rational behavior revealing patient preferences? , 2007, Health economics.
[75] E. Campbell,et al. Physician acquiescence to patient demands for brand-name drugs: results of a national survey of physicians. , 2013, JAMA internal medicine.
[76] T. Bhatia,et al. Identifying Physician Peer-to-Peer Effects Using Patient Movement Data , 2010 .
[77] Autonomous regulation and long-term medication adherence in adult outpatients. , 1998 .
[78] Pradeep K. Chintagunta,et al. Temporal Differences in the Role of Marketing Communication in New Product Categories , 2005 .
[79] Lakshman Krishnamurthi,et al. Analysis of New Product Diffusion Using a Four-Segment Trial-Repeat Model , 1994 .
[80] E. Berndt,et al. Demand Effects of Recent Changes in Prescription Drug Promotion , 2003 .
[81] Y. R. Wang,et al. The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s , 2003, Health economics.
[82] C. Winston,et al. Direct‐to‐Consumer Advertising and the Demand for Cholesterol‐Reducing Drugs* , 2002, The Journal of Law and Economics.
[83] William B. Vogt,et al. A Simple Model of Pharmaceutical Price Dynamics* , 2003, The Journal of Law and Economics.
[84] Mary Frances Luce,et al. Are Consumers Too Trusting? The Effects of Relationships with Expert Advisers , 2011 .
[85] Pierre Azoulay,et al. Do Pharmaceutical Sales Respond to Scientific Evidence , 2002 .
[86] Chuan He,et al. Direct-to-Consumer Advertising of Prescription Drugs: A Strategic Analysis , 2009, Mark. Sci..
[87] Hsien-Ming Lien,et al. Progress and compliance in alcohol abuse treatment. , 2010, Journal of health economics.
[88] Jaap E. Wieringa,et al. Early Marketing Matters: A Time-Varying Parameter Approach to Persistence Modeling , 2010 .
[89] Marc Fischer,et al. Patient-or Physician-Oriented Marketing: What Drives Primary Demand for Prescription Drugs? , 2010 .
[90] Adrian Towse,et al. Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context , 2012, Health economics.
[91] Pradeep Chintagunta,et al. Information, learning, and drug diffusion: The case of Cox-2 inhibitors , 2008 .
[92] Stefan Stremersch,et al. Drug Detailing and Doctors' Prescription Decisions: The Role of Information Content in the Face of Competitive Entry , 2016, Mark. Sci..
[93] Matthew Shum,et al. An empirical model of learning and patient spillovers in new drug entry , 2004 .
[94] J. Coleman,et al. Medical Innovation: A Diffusion Study. , 1967 .
[95] R. Chandy,et al. The Impact of Acquisitions on Innovation: Poison Pill, Placebo, or Tonic? , 2005 .
[96] Frank Windmeijer,et al. Pharmaceutical Promotion and Gp Prescription Behaviour , 2004, Health economics.
[97] Mattias Ganslandt,et al. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union. , 2004, Journal of health economics.
[98] D. McCaffrey,et al. Evaluations of care by adults following a denial of an advertisement-related prescription drug request: the role of expectations, symptom severity, and physician communication style. , 2006, Social science & medicine.
[99] Andrew T. Ching,et al. The effects of detailing on prescribing decisions under quality uncertainty , 2009 .
[100] C. Sismeiro,et al. Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules , 2008 .
[101] G. Urban,et al. Information, marketing, and pricing in the U.S. antiulcer drug market. , 1995, The American economic review.
[102] Annika Herr,et al. The welfare impact of parallel imports: a structural approach applied to the German market for oral anti-diabetics. , 2014, Health economics.
[103] R. Kravitz,et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[104] I. Cockburn,et al. Patents and the Global Diffusion of New Drugs , 2014, The American economic review.
[105] David B. Montgomery,et al. Estimating Dynamic Effects of Market Communications Expenditures , 1972 .
[106] C. Croux,et al. The Global Entry of New Pharmaceuticals: A Joint Investigation of Launch Window and Price , 2011 .
[107] Ying Xie,et al. Treatment Effectiveness and Side Effects: A Model of Physician Learning , 2013, Manag. Sci..
[108] Sriram Venkataraman,et al. Erratum - The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link? , 2008, Manag. Sci..
[109] Natalie Mizik,et al. Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions , 2004, Manag. Sci..
[110] Gregory S. Carpenter,et al. Late Mover Advantage: How Innovative Late Entrants Outsell Pioneers: , 1998 .
[111] R. Kravitz,et al. Getting to "no": strategies primary care physicians use to deny patient requests. , 2010, Archives of internal medicine.
[112] Sriram Thirumalai,et al. Product Recalls in the Medical Device Industry: An Empirical Exploration of the Sources and Financial Consequences , 2011, Manag. Sci..
[113] M. Gilly,et al. Gaining Compliance and Losing Weight: The Role of the Service Provider in Health Care Services , 2004 .
[114] Harikesh S. Nair,et al. Diffusion of New Pharmaceutical Drugs in Developing and Developed Nations , 2004 .
[115] D. Vakratsas,et al. A dual-market diffusion model for a new prescription pharmaceutical , 2008 .